SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-19-125250
Filing Date
2019-04-29
Accepted
2019-04-29 16:20:03
Documents
11
Effectiveness Date
2019-04-29

Document Format Files

Seq Description Document Type Size
1 DEFA14A d720891ddefa14a.htm DEFA14A 30629
2 GRAPHIC g720891a1.jpg GRAPHIC 4011
3 GRAPHIC g720891a2.jpg GRAPHIC 3857
4 GRAPHIC g720891a3.jpg GRAPHIC 4185
5 GRAPHIC g720891b1.jpg GRAPHIC 4204
6 GRAPHIC g720891b2.jpg GRAPHIC 809
7 GRAPHIC g720891b3.jpg GRAPHIC 4301
8 GRAPHIC g720891b4.jpg GRAPHIC 857
9 GRAPHIC g720891b5.jpg GRAPHIC 686
10 GRAPHIC g720891b6.jpg GRAPHIC 3917
11 GRAPHIC g720891snap0003_1.jpg GRAPHIC 2214
  Complete submission text file 0001193125-19-125250.txt   73066
Mailing Address 10880 WILSHIRE BLVD. SUITE 2150 LOS ANGELES CA 90024
Business Address 10880 WILSHIRE BLVD. SUITE 2150 LOS ANGELES CA 90024 (424) 248-6500
PUMA BIOTECHNOLOGY, INC. (Filer) CIK: 0001401667 (see all company filings)

IRS No.: 770683487 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-35703 | Film No.: 19776160
SIC: 2834 Pharmaceutical Preparations